DelMar Pharmaceuticals
999 West Broadway
Suite 720
British Columbia
V5Z 1K5
Canada
Tel: 1-604-629-5989
Website: http://www.delmarpharma.com/
237 articles about DelMar Pharmaceuticals
-
DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2019 Society for NeuroOncology Annual Meeting
10/29/2019
Date/Time: Friday, November 22, 2019, 6:00 PM MT Lead Author: Dr. Zhong-Ping Chen
-
DelMar Pharmaceuticals to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference
10/24/2019
DelMar Pharmaceuticals, Inc. announced that Mr. Saiid Zarrabian, president and chief executive officer of DelMar, will be a featured presenter at the 5th Annual Dawson James Small Cap Growth Conference on October 29, 2019 at 4:05 PM Eastern Time.
-
DelMar Pharmaceuticals to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 11:30 AM Central Time
10/10/2019
Mr. Zarrabian will provide an overview of the Company's business model and growth strategy and will be available for one-on-one meetings.
-
DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019
9/11/2019
DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that CEO Saiid Zarrabian will deliver a presentation on the Company and meet with investors at the Fall Investor Summit on September 16, 2019 at 1:30 PM ET in Track 1 at Essex House, 160 Central Park South in New York City
-
DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates
9/10/2019
DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the year ended June 30, 2019.
-
DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria
9/9/2019
DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that on September 6, 2019, the Company was formally notified by The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained full compliance with all criteria for continued listing on The Nasdaq Capital Market, including the applicable stockholders' equity requirement.
-
DelMar Pharmaceuticals Relocates Headquarters to San Diego, California
9/4/2019
DelMar Pharmaceuticals, Inc. announced that the Company has relocated its headquarters from Vancouver, British Columbia to San Diego, California.
-
DelMar Pharmaceuticals Anticipates Current Cash Runway Will Provide Sufficient Capital for Full Enrollment in All Three Patient Groups in Two Phase 2 Clinical Trials
8/27/2019
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that the Company anticipates that its current cash position, which includes the $6.7 million in net proceeds from the underwritten offering completed August 16, 2019,
-
DelMar Pharmaceuticals Announces Pricing Of $6.8 Million Underwritten Public Offering
8/14/2019
Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $6.8 million.
-
DelMar Pharmaceuticals Reports Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 as First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)
8/13/2019
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, provided an update on the first 20 patients enrolled in its ongoing Phase 2 clinical study investigating the first-line treatment of VAL-083 in combination with radiation therapy in newly-diagnosed, MGMT-unmethylated GBM.
-
DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)
7/31/2019
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announces it has achieved two-thirds enrollment in its ongoing Phase 2 clinical study investigating the first-line treatment of VAL-083 with radiation therapy in newly-diagnosed MGMT-unmethylated GBM.
-
DelMar Pharmaceuticals Enrolls First Patient in the Recently-Approved Adjuvant Setting Arm of Phase 2 Study of VAL-083 for the Treatment of MGMT-Unmethylated Glioblastoma Multiforme
7/24/2019
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), today announces that the first patient has been treated in the adjuvant (pre-temozolomide maintenance) trial arm of VAL-083's Phase 2 study in MGMT-unmethylated glioblastoma multiforme (GBM) being conducted at the University of Texas MD Anderson Cancer Center (MDACC)
-
DelMar Announces Relocation of Company Headquarters to San Diego
7/10/2019
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel cancer therapies, announced that it has initiated the process of relocating the Company's headquarters from Vancouver, British Columbia to San Diego, CA.
-
Delmar Pharmaceuticals Announces Termination Of Rights Offering
6/27/2019
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced it has terminated the rights offering of its securities previously announced on April 18, 2019.
-
DelMar Pharmaceuticals Announces Extension Of Rights Offering To July 12, 2019
6/25/2019
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it has completed the rights offering period and will be extending the subscription period until 5:00 PM Eastern time on July 12, 2019,
-
Delmar Pharmaceuticals Updates The Terms Of Previously Announced Rights Offering
6/11/2019
DelMar Pharmaceuticals, Inc. announced that it has adjusted certain pricing information and key dates for its previously announced rights offering.
-
DelMar Pharmaceuticals Announces Closing of Financing
6/5/2019
DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the closing of its previously announced registered direct offering of 1,170,000 shares of common stock and, in a concurrent private placement
-
DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting
6/3/2019
At the KOL forum, the Company provided an update on the ongoing Phase 1/2 clinical study investigating the front line treatment of VAL-083 with radiation therapy in newly diagnosed MGMT-unmethylated GBM.
-
DelMar Pharmaceuticals Announces $3.6 Million Registered Direct Offering
6/3/2019
DelMar Pharmaceuticals, Inc. announced that it entered into securities purchase agreements with certain institutional investors in connection with a registered direct offering of an aggregate of 1,170,000 shares of common stock and, in a concurrent private placement, warrants to purchase 760,500 shares of common stock.
-
DelMar Pharmaceuticals Updates Key Dates of Rights Offering
5/29/2019
DelMar Pharmaceuticals, Inc. provided an update to stockholders regarding the Company's rights offering and the key dates relative to the offering.